Page last updated: 2024-12-09

1-(3,4-dimethoxyphenyl)-N-propan-2-yl-1-cyclopentanecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(3,4-dimethoxyphenyl)-N-propan-2-yl-1-cyclopentanecarboxamide, also known as **N-isopropyl-1-(3,4-dimethoxyphenyl)cyclopentanecarboxamide**, is a chemical compound with potential applications in research.

Let's break down its structure and significance:

**Structure:**

* **1-cyclopentanecarboxamide:** This part indicates a cyclopentane ring (a 5-membered carbon ring) with a carboxamide group (CONH2) attached to one of the carbons.
* **1-(3,4-dimethoxyphenyl):** This part shows a phenyl ring (a 6-membered carbon ring with alternating double bonds) with two methoxy groups (OCH3) attached at the 3rd and 4th positions of the ring. This phenyl group is directly attached to the 1st carbon of the cyclopentane ring.
* **N-propan-2-yl:** This refers to an isopropyl group (CH3CHCH3) attached to the nitrogen atom of the carboxamide group.

**Importance in Research:**

While there's no widely known research on this specific compound, its structure suggests potential applications in various research areas, including:

* **Pharmacology:**
* The presence of the dimethoxyphenyl group is often found in compounds with biological activity, particularly those targeting the central nervous system.
* The isopropyl group attached to the nitrogen can influence how the molecule interacts with proteins and receptors.
* This combination of features could make this compound a candidate for studying its potential as a **psychoactive drug**, **antidepressant**, or **analgesic**.

* **Organic Chemistry:**
* This molecule can serve as a starting point for synthesizing related compounds with variations in the substituents on the phenyl ring or the cyclopentane ring.
* Researchers could study its **reaction chemistry**, exploring how it behaves under different conditions and with different reagents.

* **Materials Science:**
* The presence of the cyclopentane ring and the phenyl ring with methoxy groups could contribute to **interesting physical properties** like hydrophobicity, crystallinity, or self-assembly behavior.

**Important Note:** It's crucial to remember that the importance of a compound is determined by its specific properties and how it interacts with other molecules. The potential applications mentioned above are based on its structural features, but further research is required to confirm its actual biological activity, reactivity, or other properties.

If you have specific research goals in mind, it's best to consult with a chemist or a researcher specializing in your field for further information on this compound's potential relevance.

Cross-References

ID SourceID
PubMed CID972560
CHEMBL ID1469360
CHEBI ID112885

Synonyms (11)

Synonym
MLS000064695
smr000077478
1-(3,4-dimethoxyphenyl)-n-isopropylcyclopentanecarboxamide
CHEBI:112885
1-(3,4-dimethoxyphenyl)-n-propan-2-ylcyclopentane-1-carboxamide
HMS2459L12
CHEMBL1469360
Q27193348
1-(3,4-dimethoxyphenyl)-n-propan-2-yl-1-cyclopentanecarboxamide
SR-01000280567-1
sr-01000280567
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency112.20200.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency2.81840.075215.225339.8107AID485360
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]